Behind the Science: Behind Updates on JAK and BTK Inhibitors

Experts discuss recent research presented at ASH 2022 regarding Bruton’s tyrosine kinase (BTK) inhibitors and JAK inhibitors like ibrutinib, zanubrutinib, and ruxolitinib, for the treatment of patients with a variety of hematologic malignancies, including mantle cell lymphoma, chronic lymphocytic leukemia, and more.